Business consultant and popular culture and music researcher. Artificial intelligence researcher
Santa Barbara, CA
Joined February 2013
- Tweets87.4K
- Following7.5K
- Followers2.6K
- Likes51.7K
Eldon Edwards retweeted
Two new randomized trials of the potent GLP-1 drug retatrutide (aka "reta") showed marked relief of knee osteoarthritis. Prior work demonstrated that some of the GLP-1 benefit for knee osteoarthritis is independent of weight loss.
#AHA26 @NEJM
nejm.org/doi/full/10.1056/NE…
Eldon Edwards retweeted
Semaglutide (Ozempic) improved left atrial and diastolic function in a randomized trial of patients with preserved ejection fraction heart failure (HFpEF) and obesity (via MRI)
And achieved remission of symptoms in more than half of participants (2nd link)
#AHA26 and @NatureMedicine
nature.com/articles/s41591-0…
nature.com/articles/s41591-0…
Eldon Edwards retweeted
Nice DeepSWE score! Does it survive a lowercase filename?
Introducing MaxxBench: 89 DeepSWE tasks with small changes to the instructions or starting code. Same engineering problem, slightly different requirement.
Models clustered around 74% on DeepSWE end up 23 pp apart.
Good at coding, or good at DeepSWE? 🧵
Eldon Edwards retweeted
Why?
I wrote about this when the initial results were released
erictopol.substack.com/p/the…
1. Blood markers do not correlate with coronary inflammation which can be quantified now with AI.
The drugs assessed need to demonstrate they markedly reduce coronary inflammation, ideally before investing hundreds of millions of dollars in large clinical trials.
2. The genetic, basic science and observational studies all support the potential interventions, but that doesn't translate to initiating them in the 7th decade of life with multiple co-morbidities for secondary prevention.
3. There are more potent, durable Lp(a) blockers in large trials, one of which is in high-risk primary prevention, a far more likely cohort to derive benefit. But that will not be read out until 2031!
4. Inflammation of coronary arteries as a driver of events and drug interventions to reduce inflammation to improve outcomes have been proven, but not commonly used (i.e.. colchicine) . We will eventually see other interventions validated, including at least one of those published on today, and move the field forward.
Eldon Edwards retweeted
Today #AHA26 and @NEJM the 2 big trials of secondary prevention of heart disease with an IL-6 antibody and Lp(a) antisense oligonucleotide. No beneficial effect, overall and across all subgroups
nejm.org/doi/full/10.1056/NE…
nejm.org/doi/full/10.1056/NE…
Eldon Edwards retweeted
Is this a potential future strategy for primary prevention of atherosclerosis?
CRISPR base editing in vivo of the ANGPLT3 gene to achieve marked and durable lipid lowering.
Promising data in experimental models, including hon-human primates, moving on to clinical trials
@Nature nature.com/articles/s41586-0…
Eldon Edwards retweeted
Now there might be things to verify beyond errors - points of view, opinions, approaches, etc. But the idea that the job of humans should be checking AI work for mistakes is likely not true today, and good riddance.
Eldon Edwards retweeted
I think there is way too much concern expressed about verification of AI output in everyday work due to a risk of factual errors.
It used to be true, but data on more recent models suggest they beat human experts, including PhD specialists, in finding facts and checking claims.
Eldon Edwards retweeted
New test of which organizations have low AI capability: you haven’t updated your apps for the iPhone Duo yet.
Eldon Edwards retweeted
Some new data from Anthropic looking at the impact of AI on the sciences by field: "With current capabilities, if adopted widely, AI could take on 27–52% of the researcher time needed to produce a new study, with a median of 38% across fields..."
Here: anthropic.com/research/how-r…
Eldon Edwards retweeted
As a longtime reader (and writer of two small pieces in the 1990s) of WIRED, I was curious if the coverage of the AI era really does differ from its coverage of the early internet. A couple of experiments with Astra shows it does. Interpretation depends on your view of AI, though
Eldon Edwards retweeted
We are at the beginning of a new and exciting era to be able to program our immune system in the body (in vivo). This new review @SciImmunology nails it science.org/doi/10.1126/scii…
Eldon Edwards retweeted
A new study on brain health and estrogen:
"Greater lifetime estrogen exposure, both endogenous and exogenous, was associated with lower cerebro-vascular pathology in women and, among APOE-e4 carriers, greater cortical thickness in AD-vulnerable regions." neurology.org/doi/pdf/10.121…
Eldon Edwards retweeted
Erik is one of the economists who has been watching the impact of AI on the economy most closely, even before generative AI...
Evidence is growing that we’re turning the corner on productivity.
US productivity grew at a 3.6% annual rate this past quarter.
That’s more than double the 1.5% average from 2007-2019.
The new numbers put me further ahead for my bet with Bob Gordon about productivity growth in the 2020s. 💪
Here’s how far the US is now ahead of the CBO estimate at the start of the decade (before they knew about the pandemic or LLMs) courtesy of @jasonfurman’s
Econvitals.
Eldon Edwards retweeted
I think its technically five billionaire-funded magazines, though I believe all have editorial independence: the City Journal (Paul Singer's Foundation), Baffler (Soros Open Society), Poetry (Ruth Lily Endowment), Noema (Berggruen Institute) and Works in Progress (Stripe).
Eldon Edwards retweeted
As I have written many times in the past years, any potential financial downturn in AI stocks will not greatly change the AI trajectory
AI is not going away, companies are not slowing down adoption nor is development slowing. We still need policy & effort so that AI is used well